文献速递消化系统肿瘤

转移性结直肠癌一线治疗早期严重毒性预测因素:FFCD 2190例汇总分析

Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Fédération Francophone de Cancérologie Digestive (FFCD) trials.
PubMed 文献 · Eur J Cancer · 2021-06-12

该汇总分析纳入10项FFCD前瞻性试验的2190例转移性结直肠癌患者,评估一线化疗后3个月内≥III级早期毒性(ET3)的基线预测因素。ET3在单药、双药和三药方案中分别见于22.8%、62.8%和53.9%的患者。多因素分析显示体力状态2、碱性磷酸酶>300 UI/l、原发肿瘤未切除及三药方案与ET3发生相关,无ET3者总生存显著更长。

要点

  • ET3在单药、双药和三药方案中发生率分别为22.8%、62.8%和53.9%。
  • 体力状态2、ALP>300 UI/l、原发瘤未切除与ET3风险升高相关。
  • 无ET3患者总生存显著优于发生ET3者(HR 0.87)。

核心结论

  • ET3在各治疗 regimen 中均常见,且与特定基线特征相关。
  • ET3对转移性结直肠癌预后的临床影响需进一步研究。

研究设计与样本

  • 汇总分析10项FFCD前瞻性试验的2190例转移性结直肠癌患者个体数据。
  • ET3定义为化疗开始后3个月内发生≥III级毒性。

主要发现

  • ET3在单药组244例(22.8%)、双药组248例(62.8%)、三药组392例(53.9%)中发生。
  • 最常见ET3涉及生物学异常和/或胃肠道、全身及血管疾病。
  • 多因素分析中ET3预测因素:体力状态2 vs 0-1(OR 2.57;95% CI [1.16, 5.73];p=0.02)。
  • 三药 vs 单药(OR 2.31;95% CI [0.84, 6.33];p=0.02)、ALP>300 UI/l(OR 3.07;95% CI [1.79, 5.27];p<0.001)、原发瘤未切除 vs 切除(OR 1.59;95% CI [1.06, 2.39];p=0.02)。
  • 无ET3者中位总生存显著长于ET3者(HR 0.87;95% CI [0.80-0.96];p=0.004)。

关键数值与推荐

  • ET3定义:化疗开始后3个月内≥III级毒性。
  • 体力状态2 vs 0-1的OR为2.57(95% CI [1.16, 5.73];p=0.02)。
  • ALP>300 UI/l的OR为3.07(95% CI [1.79, 5.27];p<0.001)。
  • 原发瘤未切除 vs 切除的OR为1.59(95% CI [1.06, 2.39];p=0.02)。
  • 三药 vs 单药的OR为2.31(95% CI [0.84, 6.33];p=0.02)。

临床怎么用

  • 对体力状态2、ALP>300 UI/l或原发瘤未切除的mCRC患者,一线化疗前应加强早期毒性风险评估与监测。
  • 选择三药方案时需权衡ET3风险,尤其在高危基线特征患者中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Few studies have explored the association between baseline characteristics and the occurrence of early toxicities in patients treated with first-line chemotherapy for metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: Individual patient data of 2190 patients enrolled in 10 prospective FFCD (Fédération Francophone de Cancérologie Digestive) trials were analysed. Severe early toxicity was defined as the occurrence of grade ≥III toxicity within 3 months after initiation of chemotherapy (ET3). RESULTS: Patients received monotherapy based on 5-FU (n = 1068), a cytotoxic doublet (n = 395) or tritherapy with a cytotoxic doublet plus anti-VEGF agent or a cytotoxic triplet (n = 727). The patients received 5-FU (100%), Irinotecan (39.6%), Oxaliplatin (13.4%), Bevacizumab (29.6%) or Aflibercept (1.8%). ET3 occurred in 244 patients (22.8%) with monotherapy, 248 patients (62.8%) with doublet and 392 patients (53.9%) with tritherapy. The most frequent ET3s were related to biological abnormalities and/or gastrointestinal, general and vascular disorders. The prognostic factors for the occurrence of an ET3 in multivariate analysis were a performance status of 2 rather than 0-1 (OR 2.57; 95% CI [1.16, 5.73]; p = 0.02), tritherapy versus monotherapy (OR 2.31; 95% CI [0.84, 6.33]; p = 0.02), alkaline phosphatase > 300 UI/l (OR 3.07; 95% CI [1.79, 5.27]; p < 0.001) and non-resected primary tumour versus resection (OR 1.59; 95% CI [1.06, 2.39]; p = 0.02). Median overall survival in patients without ET3 was significantly longer than that in patients with ET3 (HR 0.87; 95% CI [0.80-0.96]; p = 0.004). CONCLUSION: ET3 is frequent whatever the treatment regimen and is associated with certain baseline characteristics. The clinical impact of ET3 on prognosis in mCRC warrants further investigation.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Breton C, Aparicio T, Le Malicot K, et al. Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Fédération Francophone de Cancérologie Digestive (FFCD) trials. Eur J Cancer. 2021. PMID: 34130228. doi:10.1016/j.ejca.2021.04.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。